Simeprevir: A macrocyclic hcv protease inhibitor

Drugs of Today

Volumn 49, Issue 12, 2013, Pages 769-779

  Talwani, R ^a   Heil, E L ^a   Gilliam, B L ^a   Temesgen, Zelalem ^b  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

GT 1; Hepatitis C virus; Macrolide; Simeprevir; TMC 435

Indexed keywords

DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; ESCITALOPRAM; ETHINYLESTRADIOL PLUS NORETHISTERONE; IMMUNOSUPPRESSIVE AGENT; METHADONE; PLACEBO; RALTEGRAVIR; RIBAVIRIN; RILPIVIRINE; SIMEPREVIR; SOFOSBUVIR; TENOFOVIR DISOPROXIL;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CLINICAL EVALUATION; CROSS RESISTANCE; DRUG METABOLISM; DRUG SAFETY; ENZYME INHIBITION; HEPATITIS C VIRUS; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TISSUE DISTRIBUTION; TREATMENT DURATION;

GT-1; HEPATITIS C VIRUS; MACROLIDE; SIMEPREVIR; TMC-435;

ANTIVIRAL AGENTS; DRUG APPROVAL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; PROTEASE INHIBITORS; SULFONAMIDES;

EID: 84892729159     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2013.49.12.2067249     Document Type: Review

References (34)

1. Ghany, M.G., Strader, D.B., Thomas, D.L., Seeff, L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49(4): 1335-74.
2. Ghany, M.G., Nelson, D.R., Strader, D.B., Thomas, D.L., Seeff, L.B., American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54(4): 1433-44.
3. Poordad, F., McCone, J., Bacon, B.R. et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364(13): 1195-206.
4. Jacobson, I.M., McHutchison, J.G., Dusheiko, G. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364(25): 2405-16.
5. Welsch, C., Jesudian, A., Zeuzem, S., Jacobson, I. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 2012, 61(Suppl. 1): i36-i46.
6. Raboisson, P., Lin, T-I., de Kock, H. et al. Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors. Bioorg Med Chem Lett 2008, 18(18): 5095-100.
7. Ingallinella, P., Altamura, S., Bianchi, E. et al. Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products. Biochemistry 1998, 37(25): 8906-14.
8. Cummings, M.D., Lindberg, J., Lin, T-I. et al. Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target. Angew Chem Int Ed Engl 2010, 49(9): 1652-5.
9. Ali, A., Aydin, C., Gildemeister, R. et al. Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance. ACS Chem Biol 2013, in press.
10. Lin, T-I., Lenz, O., Fanning, G. et al. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother 2009, 53(4): 1377-85.
11. Lenz, O., Verbinnen, T., Lin, T-I. et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 2010, 54(5): 1878-87.
12. Simmen, K., Lenz, O., Lin, T-I. et al. In vitro activity and preclinical pharmacokinetics of the HCV protease inhibitor TMC435350. 58th Annu Meet Am Assoc Study Liver Dis (November 2-6, Boston) 2007, Abst 1390.
13. Reesink, H.W., Fanning, G.C., Farha, K.A. et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 2010, 138(3): 913-21.
14. Simion, A., Mortier, S., Peeters, M., Beaumont-Mauviel, M., Ouwerkerk-Mahadevan, S. Pharmacokinetics of simeprevir (TMC435) in volunteers with severe renal impairment. 8th Int Workshop Clin Pharmacol Hepatitis Ther (June 26-27, Cambridge) 2013.
15. Ouwerkerk-Mahadevan, S., Simion, A., Spittaels, K., Beaumont-Mauviel, M. Pharmacokinetics of simeprevir (TMC435) in volunteers with moderate or severe hepatic impairment. 48th Annu Meet Eur Assoc Study Liver (EASL) (April 24-28, Amsterdam) 2013, Abst 887.
16. Manns, M., Reesink, H., Berg, T. et al. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial. Antivir Ther (Lond) 2011, 16(7): 1021-33.
17. Lenz, O., de Bruijne, J., Vijgen, L. et al. Efficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus-infected patients following TMC435 monotherapy. Gastroenterology 2012, 143(5): 1176-8.e1-6.
18. Moreno, C., Berg, T., Tanwandee, T. et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol 2012, 56(6): 1247-53.
19. Fried, M.W., Buti, M., Dore, G.J. et al. TMC435 in combination with peginterferon and ribavirin in treatment-naive patients: final analysis of the PILLAR phase IIb Study (TMC435-C205). 62nd Annu Meet Am Assoc Study Liver Dis (AASLD) (November 4-8, San Francisco) 2011.
20. Zeuzem, S., Berg, T., Gane, E. et al. TMC435 with peginterferon and ribavirin in treatment-experienced HCV genotype 1 patients: the ASPIRE study, a randomised phase IIb trial. 47th Annu Meet Eur Assoc Study Liver (EASL) (April 18-22, Barcelona) 2012.
21. Jacobson, I., Dore, G.J., Foster, G. et al. Simeprevir (Tmc435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-1, a phase III trial. Dig Dis Week (May 18-21, Orlando) 2013, Abst Sa2072.
22. Poordad, F., Manns, M., Marcellin, P. et al. Simeprevir (Tmc435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from Quest-2, a phase III trial. Dig Dis Week (May 18-21, Orlando) 2013, Abst 869a.
23. Lawitz, E., Forns, X., Zeuzem, S. et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: results from PROMISE, a phase III trial. Dig Dis Week (May 18-21, Orlando) 2013, Abst 869b.
24. Dieterich, D.T., Rockstroh, J.K., Orkin, C. et al. Simeprevir (TMC435) with peginterferon/ribavirin in patients co-infected with chronic genotype-1 HCV and HIV-1: week-24 interim analysis of the TMC435-C212 study. 20th Conf Retroviruses Opportunistic Infect (CROI) (March 3-6, Atlanta) 2013, Abst 154LB.
25. Lawitz, E., Rodriguez-Torres, M., Younossi, Z. et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. Dig Dis Week (May 18-21, Orlando) 2013.
26. Fried MW, Poordad F, Zeuzem S, et al. Safety and tolerability of simeprevir (TMC435) in combination with peginterferon alfa-2a and ribavirin for treatment of HCV genotype 1 infection in treatment-naïve and -experienced patients (Phase IIb PILLAR and ASPIRE trials). 63rd Annu Meet Am Assoc Study Liver Dis (November 9-13, Boston) 2012, Abst.
27. Lenz, O., Fevery, B., Vijen, L. et al. Resistance profile of TMC435 in HCV genotype 1-infected patients: virologic analyses of the PILLAR and ASPIRE Phase IIb trials. Int HIV Hepat Virus Drug Resist Workshop Curativ Strategies (June 5-9, Sitges) 2012, Abst 20.
28. Sekar, V., Verloes, R., Meyvisch, P., Spittaels, K., Akuma, S.H., De Smedt, G. Evaluation of metabolic interactions for TMC435 via cytochrome P450 (CYP) enzymes in healthy volunteers. 45th Annu Meet Eur Assoc Study Liver (EASL) (April 14-18, Vienna) 2010, Abst.
29. Ouwerkerk-Mahadevan, S., Simion, A., Spittaels, K., Peeters, M., Beaumont-Mauviel, M. No pharmacokinetic interaction between the investigational HcV protease inhibitor simeprevir (TMc435) and an oral contraceptive containing ethinylestradiol and norethindrone. 63rd Annu Meet Am Assoc Study Liver Dis (November 9-13, Boston) 2012, Abst.
30. Ouwerkerk-Mahadevan, S., Beaumont-Mauviel, M., Simion, A. et al. The pharmacokinetic interaction between the investigational HCV NS3/4A protease inhibitor TMC435 and escitalopram. 62nd Annu Meet Am Assoc Study Liver Dis (November 4-8, San Francisco) 2011, Abst.
31. Ouwerkerk-Mahadevan, S., Beaumont-Mauviel, M., De Smedt, G., Peeters, M., Akuma, S.H., Sekar, V. The pharmacokinetic interaction between the investigational NS3/4A HCV protease inhibitor TMC435 and methadone. 62nd Annu Meet Am Assoc Study Liver Dis (November 4-8, San Francisco) 2011, Abst.
32. Simion, A., Ouwerkerk-Mahadevan, S., Mortier, S., Peeters, M., Janssens, L., Beaumont-Mauviel, M. Simeprevir (TMC435) does not prolong the QT/QTc interval in healthy volunteers. 8th Int Workshop Clin Pharmacol Hepatitis Ther (June 26-27, Cambridge) 2013, Abst.
33. Ouwerkerk-Mahadevan, S., Sekar, V., Simion, A., Peeters, M., Beaumont-Mauviel, M. The pharmacokinetic interactions of HCV protease inhibitor TMC435 with antiretroviral agents in healthy volunteers. 50th Annu Meet Infect Dis Soc Am (IDSA) (October 17-21, San Diego) 2012, Abst 1618.
34. Ouwerkerk-Mahadevan, S., Simion, A., Mortier, S., Peeters, M., Beaumont-Mauviel, M. No clinically significant interaction between the investigational HCV protease inhibitor simeprevir (TMC435) and the immunosuppressive agents cyclosporine and tacrolimus. 63rd Annu Meet Am Assoc Study Liver Dis (November 9-13, Boston) 2012, Abst.